Nexalin Technology (NXL US): Synthetic Expert Call Transcript (11 Oct 2026)
Commercial traction remains constrained by zero insurance reimbursement and low volume, with Q2 2026 revenue printing at just $12.16 thousand...
84 Views
IPO Databook: Nexalin Technology (NXL US) - Oct 2026
Nexalin Technology, Inc. is a medical device company developing innovative neurostimulation products to address the global mental health...
82 Views
Quiddity Leaderboard ASX Sep25: Methodology Change Confirmed; Good Performance; Final Expectations
We have revised our final expectations for the September 2025 index review due to the deletion of Adriatic Metals which was one of our expected...
922 Views